ARKGvsXBIETF Comparison
VS
ARK Genomic Revolution ETF (ARKG) belongs to the BioTech & Genomics segment. State Street SPDR S&P Biotech ETF (XBI) is part of the US Health Care segment. ARKG's top 3 sector exposures are Health Care and Information Technology. In contrast, XBI's top sector exposures are Health Care ARKG is more expensive with a Total Expense Ratio (TER) of 0.75%, versus 0.35% for XBI. ARKG is down -2.36% year-to-date (YTD) with -$17M in YTD flows. XBI performs better with 6.95% YTD performance, and -$91M in YTD flows. Run a side-by-side ETF comparison of ARKG and XBI below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
ARKG vs XBI performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 04/29/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | ARKG XBI | +14.98%+1.50% | -9.13%+2.42% | -2.36%+6.95% | +27.92%+58.67% | -2.43%+59.44% | -67.96%-2.95% |
| Flows | ARKG XBI | -$2M+$660M | -$53M-$368M | -$17M-$91M | -$66M+$387M | -$583M-$1.39B | -$3.03B+$843M |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | ARKG XBI | +43.08%+30.04% | +41.66%+25.97% | +42.62%+27.37% | +45.37%+32.70% |
| Max drawdown | ARKG XBI | -20.97%-7.98% | -27.52%-9.66% | -51.98%-32.94% | -80.16%-54.69% |
| Max drawdown duration | ARKG XBI | 90d42d | 97d76d | 1015d331d | 1765d1754d |
Trading data
ARKG | XBI | |
Last sale 5/1/2026 at 1:30 PM | $30.30 | $130.42 |
| Previous close 04/29/2026 | $29.87 | $131.33 |
| Consolidated volume 04/29/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of April 30, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
ARKG
is actively managed and doesn’t replicate an indexARKG | XBI | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 5/1/2026 at 1:30 PM
Live
Closed
ARKG | XBI | |
|---|---|---|
| Last price | $30.30 | $130.42 |
| 1D performance | +1.44% | -0.69% |
| AuM | $1.13 B | $8.26 B |
| E/R | 0.75% | 0.35% |
Characteristics
ARKG | XBI | |
|---|---|---|
| Management strategy | Active | Passive |
| Provider | Ark Investment | State Street Investment Management |
| Benchmark | - | S&P Biotechnology Select Industry Index |
| N° of holdings | 27 | 122 |
| Asset class | - | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | April 2, 2019 | January 31, 2006 |
| ESG | No | No |
Advertisement
Exposure
Countries
ARKG
USA
70.4%
Switzerland
9.23%
Other
20.37%
XBI
USA
95.16%
Other
4.84%
Sectors
ARKG
Health Care
78.38%
Other
21.62%
XBI
Health Care
86.79%
Other
13.21%
Advertisement
Diversification
ARKG
Total weight of top 15 holdings out of 15
62.5%
XBI
Total weight of top 15 holdings out of 15
19.71%
Top 15 holdings
Data as of March 31, 2026
ARKG
CRISPR THERAPEUTICS
9.23%
10X GENOMICS INC
6.30%
BEAM THERAPEUTICS
4.86%
PERSONALIS INC
4.69%
NATERA
4.48%
ILLUMINA
4.45%
GUARDANT HEALTH INC
4.21%
INTELLIA THERAPEUTICS INC
3.58%
CAREDX INC/D
3.56%
RECURSION PHARMACEUTICALS
3.54%
ABSCI
3.27%
VERACYTE INC/D
2.98%
ADAPTIVE BIOTECHNOLOGIES
2.71%
NURIX THERAPEUTICS
2.45%
SEMA4 HOLDINGS CORP
2.19%
XBI
APELLIS PHARMACEUTICALS
1.83%
ALKERMES
1.45%
MADRIGAL PHARMACEUTICALS INC
1.38%
TG THERAPEUTICS
1.35%
INSMED
1.34%
SCHOLAR ROCK HOLDING CORP
1.30%
US03770N1019
1.28%
PROTAGONIST THERAPEUTICS INC
1.25%
US86627T1088
1.24%
UTD THERAPEUT
1.24%
US74006W2070
1.24%
ARROWHEAD PHARMACEUTICALS INC
1.23%
COGENT BIOSCIENCES
1.22%
BRIDGEBIO PHARMA
1.19%
PTC THERAPEUTI/D
1.18%
Frequently asked questions about ARKG and XBI
How have the ARKG and XBI ETFs performed in 2026?
As of April 29, 2026, ARKG is down -2.36% year-to-date (YTD), while XBI has returned 6.95%. That puts XBI better performer ahead so far this year.
Which ETF is attracting more investor money: ARKG or XBI?
Year-to-date, the ARKG ETF saw -$17M in flows, compared to -$91M for XBI.
Which ETF is more volatile: ARKG or XBI?
Over the past year, ARKG had a volatility of 41.66%, while XBI experienced 25.97%.
Which ETF is bigger: ARKG or XBI?
As of April 29, 2026, ARKG holds $1.13 B in assets under management (AUM), while XBI manages $8.26 B.
What sectors do the ARKG and XBI ETFs invest in?
ARKG leans toward sectors like Health Care. Meanwhile, XBI focuses on Health Care.
What are the top holdings of the ARKG ETF and XBI ETF?
ARKG top holdings include CRISPR THERAPEUTICS, 10X GENOMICS INC and BEAM THERAPEUTICS. XBI holds in its top three: APELLIS PHARMACEUTICALS, ALKERMES and MADRIGAL PHARMACEUTICALS INC.
Which ETF is more diversified: ARKG or XBI?
ARKG holds 27 securities with 62.5% of its assets in the top 15. XBI has 151 securities and a top 15 weight of 19.71%.
Advertisement
Latest news about ARKG & XBI
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
XBI
Are Biotechnology ETFs In the Midst of a Comeback?
August 20, 2025
XBI
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
XBI
Biotech ETFs – Investing in Health Innovation
July 21, 2022
ARKG
XBI
Advertisement
Advertisement
